1-(3-carboxyprop-1-yl)-2-(4-fluorobenzyl)-thio-5-(2-methylpyrazol-4-ylmethyl)-pyrimidin-4-one | 304902-90-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 1-(3-carboxyprop-1-yl)-2-(4-fluorobenzyl)-thio-5-(2-methylpyrazol-4-ylmethyl)-pyrimidin-4-one
• 英文别名: 4-[2-[(4-Fluorophenyl)methylsulfanyl]-5-[(1-methylpyrazol-4-yl)methyl]-4-oxopyrimidin-1-yl]butanoic acid
• CAS: 304902-90-7
• 化学式: C₂₀H₂₁FN₄O₃S
• 分子量: 416.476
• InChiKey: VPAKSJPRCRSSCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-氨基乙基联苯 、 1-(3-carboxyprop-1-yl)-2-(4-fluorobenzyl)-thio-5-(2-methylpyrazol-4-ylmethyl)-pyrimidin-4-one 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 生成 1-(3-(4-phenylbenzylaminocarbonyl)-prop-1-yl)-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one
  参考文献：
  名称：

  Potent, orally active inhibitors of lipoprotein-associated phospholipase A2: 1-(biphenylmethylamidoalkyl)-pyrimidones

  摘要：

  A series of 1-(biphenylmethylamidoalkyl)-pyrimidones has been designed as nanomolar inhibitors of recombinant lipoprotein-associated phospholipase A(2) with high potency in whole human plasma. 5-(Pyrazolylmethyl) derivative 16 and 5-(methoxypyrimidinylmethyl) derivative 27 demonstrated excellent pharmacodynamic profiles which correlated well with their pharmacokinetic effects. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00678-3

文献信息

• 1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A 2
  作者：Jackie C. Bloomer、Helen F. Boyd、Deirdre M.B. Hickey、Robert J. Ife、Colin A. Leach、Colin H. Macphee、Kevin J. Milliner、Ivan L. Pinto、D.Anthony Rawlings、Stephen A. Smith、Ian G. Stansfield、Steven J. Stanway、Maxine A. Taylor、Colin J. Theobald、Caroline M. Whittaker

  DOI：10.1016/s0960-894x(01)00346-8

  日期：2001.7

  The lipophilic 1-substituent in a series of 1-((amidolinked)-alkyl)-pyrimidones, inhibitors of recombinant lipoprotein-associated phospholipase A(2), has been modified to give inhibitors of high potency in human plasma and enhanced physicochemical properties. Phenylpiperazineacetamide derivative 23 shows very promising oral activity. (C) 2001 Elsevier Science Ltd. All rights reserved.
• US6953803B1
  申请人：——

  公开号：US6953803B1

  公开（公告）日：2005-10-11
• US7115616B2
  申请人：——

  公开号：US7115616B2

  公开（公告）日：2006-10-03
• Potent, orally active inhibitors of lipoprotein-associated phospholipase A2: 1-(biphenylmethylamidoalkyl)-pyrimidones
  作者：Helen F. Boyd、Stephen C.M. Fell、Deirdre M.B. Hickey、Robert J. Ife、Colin A. Leach、Colin H. Macphee、Kevin J. Milliner、Ivan L. Pinto、D.Anthony Rawlings、Stephen A. Smith、Ian G. Stansfield、Steven J. Stanway、Colin J. Theobald、Caroline M. Whittaker

  DOI：10.1016/s0960-894x(01)00678-3

  日期：2002.1

  A series of 1-(biphenylmethylamidoalkyl)-pyrimidones has been designed as nanomolar inhibitors of recombinant lipoprotein-associated phospholipase A(2) with high potency in whole human plasma. 5-(Pyrazolylmethyl) derivative 16 and 5-(methoxypyrimidinylmethyl) derivative 27 demonstrated excellent pharmacodynamic profiles which correlated well with their pharmacokinetic effects. (C) 2001 Elsevier Science Ltd. All rights reserved.